Personalized, medically supervised plans to support healthy and sustainable weight management.
Semaglutide (GLP-1)
Semaglutide is a GLP-1 RA (Glucagon-Like Peptide-1 Receptor Agonist) medication that reduces hunger, slows gastric emptying, and increases feelings of fullness, therefore helping with lower calorie intake and gradual weight loss over time. It is administered once weekly as part of a comprehensive weight management plan consisting of appropriate diet control and increased level of physical activity and intended for long-term treatment in eligible patients.
Tirzepatide (dual GIP/GLP-1)
Tirzepatide is a dual GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 RA medication that stimulates insulin release and slows gastric emptying providing superior blood sugar control and generally leading to greater weight loss compared to medications that only target GLP-1. It is also administered once weekly paired with diet control and physical activity and is designed for ongoing weight management in eligible patients.
Personalized, medically supervised plans to support healthy and sustainable weight management.
Semaglutide (GLP-1)
Semaglutide is a GLP-1 RA (Glucagon-Like Peptide-1 Receptor Agonist) medication that reduces hunger, slows gastric emptying, and increases feelings of fullness, therefore helping with lower calorie intake and gradual weight loss over time. It is administered once weekly as part of a comprehensive weight management plan consisting of appropriate diet control and increased level of physical activity and intended for long-term treatment in eligible patients.
Tirzepatide (dual GIP/GLP-1)
Tirzepatide is a dual GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 RA medication that stimulates insulin release and slows gastric emptying providing superior blood sugar control and generally leading to greater weight loss compared to medications that only target GLP-1. It is also administered once weekly paired with diet control and physical activity and is designed for ongoing weight management in eligible patients.